Umoja Biopharma Announces $100 Million Oversubscribed Series C Financing to Propel In Vivo CAR T Pipeline Toward Key Oncology Clinical Milestones
Umoja Biopharma, a biotechnology company focused on advancing in vivo CAR T therapies for cancer treatment, has announced the successful completion of its $100 million oversubscribed Series C financing round. The funds will be used to accelerate the company’s innovative cancer treatments and move its lead in vivo CAR T candidates through critical clinical milestones in oncology.
The Series C round was led by a group of high-profile investors, including both new and existing partners, who recognize the potential of Umoja’s platform to revolutionize cancer immunotherapy. The company’s approach involves developing CAR T therapies that can be directly administered in vivo, rather than requiring the complex and costly process of engineering T-cells outside the body. This novel strategy has shown great promise in preclinical studies and is aimed at making CAR T therapy more accessible and effective for patients battling various cancers.
“This significant oversubscribed funding reflects the tremendous interest and confidence in Umoja’s unique in vivo CAR T platform,” said Dr. W. Keith MacDonald, CEO of Umoja Biopharma. “With this capital, we are poised to take critical steps forward in advancing our pipeline, and we are focused on achieving key clinical milestones that could offer new hope to cancer patients who need better treatment options.”
The company’s in vivo CAR T therapies are designed to improve upon the current generation of CAR T treatments, which involve extracting a patient’s T-cells, modifying them in the lab, and then reinfusing them into the patient. Umoja’s approach, by administering CAR T directly in vivo, could eliminate several of the challenges associated with traditional methods, such as cost, complexity, and time constraints, while potentially improving the therapeutic outcomes for patients with cancers like lymphoma and leukemia.
With the newly raised $100 million, Umoja Biopharma plans to advance its clinical trials and expand its pipeline of in vivo CAR T therapies. The company is focused on moving its lead programs forward, which are designed to target both hematologic and solid tumors. By doing so, Umoja hopes to bring novel treatments to market that could extend survival and improve the quality of life for patients facing aggressive cancers.
“We are excited to partner with Umoja Biopharma as they continue to innovate in the CAR T space,” said one of the leading investors in the Series C round. “The company’s in vivo approach offers a fresh perspective on how to deliver effective cancer therapies, and we believe they are well-positioned to make significant advancements in the field of oncology.”
The Series C funding will also support the growth of Umoja’s research and development capabilities, the expansion of its clinical team, and the optimization of its manufacturing process. As the company advances toward clinical trials, it aims to demonstrate the safety and efficacy of its treatments, setting the stage for future regulatory filings and commercial partnerships.
Umoja’s innovative approach to CAR T therapy aligns with the growing trend of developing next-generation cancer treatments that offer greater accessibility and efficacy. The oversubscribed Series C round provides the financial backing needed for the company to continue its pioneering work in the oncology space and work toward providing patients with more effective and less invasive treatment options.
With this new funding, Umoja Biopharma is positioned to become a leader in the field of in vivo CAR T therapies, pushing the boundaries of what’s possible in cancer immunotherapy and working toward making these life-saving treatments more accessible to patients worldwide.
